Abstract
To the Editor: We congratulate Walmsley and Sumithran1 for their excellent review on medications for the management of obesity in adults. We also wish to highlight a safety signal for thyroid cancer with glucagon-like peptide 1 (GLP-1) receptor agonists, which is a relevant issue to prescribers given the widespread use of these agents for obesity.
Preclinical studies in rodents demonstrated that all GLP-1 receptor agonists caused thyroid C cell tumours...
Preclinical studies in rodents demonstrated that all GLP-1 receptor agonists caused thyroid C cell tumours...
Original language | English |
---|---|
Pages (from-to) | 187 |
Number of pages | 1 |
Journal | Medical Journal of Australia |
Volume | 219 |
Issue number | 4 |
Early online date | 4 Jul 2023 |
DOIs | |
Publication status | Published - Aug 2023 |
Keywords
- adverse events
- Cancer
- Diabetes mellitus, type 2
- Endocrine gland neoplasms
- Obesity
- Pharmaceuticals